Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 3/20 | 0.40 |
| ▸ | PPARG | P37231 | 6/20 | 0.40 |
| ▸ | PPARA | Q07869 | 6/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 5/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
| ▸ | BCL9 | O00512 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5358807 | 0.89 | CNR1 (0.46) | TACR2PPARGPPARATRPV1CNR1 | |
| SCHEMBL5364836 | 0.87 | HPGD (0.46) | TACR2PPARGPPARATRPV1CNR1 | |
| SCHEMBL5364230 | 0.85 | PPARA (0.43) | PPARGPPARACNR1PLA2G10PLA2G2A | |
| SCHEMBL5364805 | 0.85 | PPARG (0.51) | PPARGPPARAPPARD | |
| SCHEMBL5354670 | 0.82 | PPARA (0.53) | TACR2PPARGPPARA | |
| SCHEMBL5364799 | 0.81 | PPARA (0.47) | PPARGPPARATRPV1CNR1CNR2 | |
| SCHEMBL6149147 | 0.81 | PPARG (0.42) | PPARGPPARACNR1PPARDCA1 | |
| SCHEMBL5353980 | 0.80 | CNR1 (0.48) | PPARGPPARATRPV1CNR1CNR2 | |
| SCHEMBL5358284 | 0.78 | PPARA (0.45) | TACR2PPARGPPARAPPARDBCL9 | |
| SCHEMBL5358154 | 0.76 | TRPV1 (0.48) | PPARGPPARATRPV1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220880-B2 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-22 | — | — | US | claimed |
| US-20060111406-A1 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2006-05-25 | — | — | US | claimed |
| EP-1233964-B1 | NEW USE AND NOVEL N-AZABICYCLO-AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | claimed |
| EP-1517882-A1 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-30 | — | — | EP | claimed |
| WO-2004000789-A9 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2004-03-11 | — | — | WO | claimed |
| WO-2004000789-A1 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-12-31 | — | — | WO | claimed |
| US-7220880-B2 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220880-B2 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060111406-A1 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2006-05-25 | — | — | US | disclosed |
| EP-1233964-B1 | NEW USE AND NOVEL N-AZABICYCLO-AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| EP-1517882-A1 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000789-A9 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2004-03-11 | — | — | WO | disclosed |
| US-6683090-B1 | N-(1-AZABICYCLO(2.2.2)OCT-3-YL)PROPENAMIDE DERIVATIVES; PSYCHOTIC AND INTELLECTUAL IMPAIRMENT DISORDERS | ASTRAZENECA AB (SE) | 2004-01-27 | — | — | US | disclosed |
| WO-2004000789-A1 | AMIDE LINKER PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111406-A1 | Amide linker peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | TACR2 971/4885PPARG 1/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.